Mon Sep 23 17:36:45 UTC 2024: ## Bristol-Myers Squibb Sees Mixed Investor Activity in Q2

**New York, NY** – Bristol-Myers Squibb (BMY) experienced a mixed bag of investor activity during the second quarter, according to recent SEC filings. While some institutional investors decreased their stakes in the biopharmaceutical company, others significantly increased their holdings.

Commonwealth Financial Services LLC, for example, reduced its BMY stake by 7.1% in Q2, selling 595 shares. However, EverSource Wealth Advisors LLC increased its position by 14.1%, acquiring an additional 703 shares.

Other notable investors included Fairscale Capital LLC and Itau Unibanco Holding S.A., which both purchased new positions in BMY during the quarter. Independent Franchise Partners LLP raised its stake by 4.0% while Fidelis Capital Partners LLC saw a significant 85.1% increase in its holdings.

Overall, institutional investors and hedge funds currently hold 76.41% of BMY’s stock.

Research analysts are also divided in their opinions on BMY. While Barclays raised its price target to $42.00 and gave the stock an “underweight” rating, Deutsche Bank Aktiengesellschaft lowered its target to $45.00 and assigned a “hold” rating. Jefferies Financial Group, TD Cowen, and Cantor Fitzgerald also issued reports, with varied price targets and ratings.

BMY’s Q2 earnings report, released on July 26th, showed the company exceeding analyst expectations, reporting $2.07 EPS compared to the consensus estimate of $1.64. Revenue also surpassed expectations, reaching $12.20 billion.

Despite the positive earnings report, BMY’s stock performance remains volatile. The company has a current ratio of 1.16, a quick ratio of 1.02, and a debt-to-equity ratio of 2.86. The stock’s 52-week low is $39.35, while its 52-week high is $59.46.

Overall, the mixed investor sentiment and analyst opinions suggest a period of uncertainty for BMY. However, the company’s strong earnings performance and continued commitment to research and development may drive future growth.

Read More